At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based CEO’ operating in the Medical Device space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Kevin Lee
Chief Executive Officer of Bicycle Therapeutics
Kevin Lee, Ph.D., MBA, is chief executive officer of Bicycle Therapeutics. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programmes across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions. Kevin studied pharmaceutical sciences at Nottingham University followed by a Ph.D. in pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Kevin is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.
Follow Kevin Lee:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Emil Hewage
Co-Founder & CEO of BIOS
Emil’s academic background is as a PhD researcher in computational neuroscience and machine learning. He brings knowledge of neural signalling and signal processing with over 7 year’s industrial & academic R&D experience. He has previously developed medical devices with Siemens Healthcare and Sphere Medical as well as having held roles in finance and medical and cleantech startups.
Follow Emil Hewage:
About BIOS: A full-stack neural interface platform, that uses AI to decode and encode the signals from to the body, to treat chronic health conditions.
Jacob Rothman
CEO and Co-Founder of Perch
Co-Founder and CEO of Perch. Trying to revolutionize fitness technology. Learning something new everyday. MIT Grad.
Follow Jacob Rothman:
About Perch: Perch utilizes cameras mounted to weight racks to measure, store, and analyze weightlifting performance.
John Lewandowski
CEO of Disease Diagnostic Group
John R. Lewandowski (Founder/CEO) is a PhD student at MIT in the Mechanosynthesis Group underneath Prof. John Hart, focusing on low-cost diagnostics leveraging the physics of microparticles, optics, magnetism, and self assembly. His interest in disease diagnostics goes back all the way to high school, where he was a two-time state champion in Disease Detectives in Science Olympiad. He graduated in 2012 from Case Western Reserve University with bachelor’s degrees in mechanical engineering, entrepreneurship, economics, and business management, continuing on with a Masters of Engineering and Management degree from CWRU. He has experience in medical device design and commercialization with internships at Cleveland Clinic, General Electric, CWRU, as well as a drug-delivery start-up Recon Therapeutics. He’s also been Managing Partner at Lew & Dowski Capital, LLC for the past four years, scaling a boutique investment fund based on an innovative supply and demand model in a niche market with a quickly growing NAV of $500,000. He has been recognized as a National Defense Science and Engineering Graduate Fellow, a NSF Graduate Research Fellow, a Hertz Foundation Fellowship Finalist, a Tata Fellow, a Don Richards Fellow, a Tau Beta Pi Fellow, a member of Phi Beta Kappa Society, a Forbes 30 under 30 nominee, distinguished in Think Magazine’s 30 under Thirty and Foreign Policy’s 100 Leading Thinkers, and a Lemelson-MIT Prize Inventor. He’s been an author on a dozen papers and holds one patent on drug reconstitution.
Follow John Lewandowski:
About Disease Diagnostic Group, Lew & Dowski Capital: DDG is a pre-revenue medical device company specializing in the development of rapid, accurate, and inexpensive disease diagnostic tests.
Caroline Loew
President & Chief Executive Officer of Glympse Bio
Caroline Loew is the President and Chief Executive Officer at Glympse Bio.
Follow Caroline Loew:
About Glympse Bio: Glympse Bio is a biotechnology company that transforms disease detection and predict treatment response.
Eric Mayes
CEO of Endomag
Dr Mayes has over 20 years’ experience in developing and leading materials technology companies. Prior to joining Endomag as CEO in 2010, Eric held executive positions in Cambridge Display Technology (CDT) and NanoMagnetics. He was named the Royal Society of Chemistry’s ‘Entrepreneur of the Year 2003’ for his founding role in NanoMagnetics. Eric is an advisor to the University of Texas at Austin’s ‘Texas Health Catalyst’ and the European Healthtech Translation Advisory Board (HealthtechTAB). A US-UK dual national, he holds a BSc in Physics from Arkansas State University and a PhD in Chemistry from the University of Bath. Eric is a Fellow of the Royal Society of Chemistry.
Follow Eric Mayes:
About Endomag: Endomag is a medical technology company devoted to improving breast cancer care through its magnetic sensing technologies.
Daniel Carballo
CEO & Co-Founder of Encora Therapeutics
Daniel Carballo is the CEO at Encora Therapeutics.
Follow Daniel Carballo:
About Encora Therapeutics: Encora helps people with neurodegenerative movement disorders regain independence and control in their lives.
Romain Marmot
Deputy CEO, Chief Operating Officer – US, Oncology Division Coordinator, Co-founder of Voluntis
Romain is Chief Operations Officer of Voluntis and heads the company’s North American operations in Cambridge, MA. He has more than 15 years of experience in digital health and software medical devices. He holds an MSc from École Centrale Paris in applied mathematics.
Follow Romain Marmot:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Pierre Leurent
Founder & CEO of Voluntis
Pierre has more than 15 years of international experience in software medical devices, disease management and telemedicine solutions in Europe and the United States. Before founding Voluntis in 2001, Pierre worked with General Electric Medical Systems and with HealthCenter Internet Services, an online cardiology EMR solution vendor in San Francisco. In addition, Pierre is the Director of Syntec Numérique, where he leads the telemedicine workgroup, co-leader of CSIS-CSF’s e-health workgroup and e-health advisor within Nouvelle France Industrielle’s health steering committee. Pierre is a graduate of the Ecole Centrale Paris engineering school.
Follow Pierre Leurent:
About Voluntis: Voluntis is a healthcare-related software company specialized in patient relationship management.
Vitor Pamplona
CEO of EyeNetra
I am mostly known for starting a smart, connected wave of technologies in eye care. We created the first smartphone add-on to measure the refractive error of the eyes, the first at-home vision test to be self-administered by the patient alone, the first to use virtual reality to improve the experience, the first tele-optometry deployment, the first to allow patients to track their own eyesight over time, and the first to complete an integrated solution to remote refractive care worldwide. All of them are marketed products these days (EyeNetra, EyeQue, OnSight, Blink). My research also established the concept and first prototype of a 3D display that eliminates the need for corrective eyewear altogether (Tailored Displays). I operate in the triple frontier between optics, computer science, and vision science from early research to post-breakeven. We have created and deployed refractive innovations that enable eyecare providers to fulfill a vision correction to the ~4.5B people in need. That vision correction is delivered in various form factors: eyeglasses, contacts, Lasik surgery, self-correcting displays, holograms, virtual and augmented reality add-ons, etc; and through a range of companies and products my technology helped create and deploy over the past years. My executive style is based on transparency, freedom, diversity, and trust. Besides the technical knowledge, I have hands-on experience in corporate governance, marketing, sales, fundraising and finances, business development, and intellectual property, both in an NGO and Startup settings. In the side, I co-founded PUB-Boston and the SciBr Foundation to help catalyze Brazilian innovation worldwide. In the past, I co-founded one of the biggest Java User Groups in Brazil (JavaFree), the first Portuguese-speaking on-line portal for Ruby (RubyOnBr), the first 3D game engine for feature phones (M3GE), deployed 11 other open source projects while working full time as a software developer and architect.
Follow Vitor Pamplona:
About EyeNetra, Path Check, SciBr Foundation: EyeNetra is a developer of an eye diagnostics platform used to measure the correction of users’ vision through smartphone-based technology.
Danielle Zurovcik
Founder & CEO of WiCare
Danielle Zurovcik is the founder and CEO of WiCare.
Follow Danielle Zurovcik:
About WiCare: WiCare develops innovative medical devices that are clinically effective and affordable worldwide.
Billy Boyle
CEO and Co-Founder of Owlstone Nanotech
Since co-founding Owlstone, Billy has been overseeing the development and implementation of the detection technology with nanotechnology foundry partners. He is also active in business development, demonstrating to partners how the Owlstone technology can used to realise a paradigm shift in detection applications and deployment scenarios. Billy is heavily involved in the creation and realisation of new technologies and IP. Prior to joining Owlstone Billy was a Research Associate in the Microsystems and Nanotech group at Cambridge University. In an academic / industry consortium he designed and developed silicon-opto hybrid devices for next generation telecoms systems.
Follow Billy Boyle:
About Owlstone Nanotech: OWLSTONE is a platform technology, where regardless of the application, hardware remains the same & the app is enabled through software.
Joanna Burnett
Co-founder and CEO of GPrX Data
Follow Joanna Burnett:
About GPrX Data: GPrX Data translates NHS practice level prescribing data into easily-reviewed intelligence.
Andrew Baker Campbell
CEO of LEX Diagnostics
Andrew Baker-Campbell is the CEO of LEX Diagnostics.
Follow Andrew Baker Campbell:
About LEX Diagnostics: LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care.
Andrew Baker Campbell
CEO of LEX Diagnostics
Andrew Baker-Campbell is the CEO of LEX Diagnostics.
Follow Andrew Baker Campbell:
About LEX Diagnostics: LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care.